MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting - Seite 4

 

 

This communication contains certain forward-looking statements concerning MOR208 (XmAb5874) and its therapeutic and commercial potential. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties, including the risks and uncertainties of developing drugs that are safe and effective generally and the risks that the clinical trial results presented here may not be replicated in future clinical trial.. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys and Xencor disclaim any intention or obligation to update any of these forward-looking statements.

 

 

For more information, please contact:

 

MorphoSys AG	Xencor, Inc.
Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR   Mario Brkulj Associate Director Corporate Communications & IR   Alexandra Goller Specialist Corporate Communications & IR   Jessica Rush Specialist Corporate Communications & IR   Tel: +49 (0) 89 / 899 27-404 [e-mail]	Jason Spark Canale Communications for Xencor [e-mail] [phone]

Media Release (PDF)

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1878010

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / Munich Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;